Seminars in Oncology
Volume 37, Issue 1 , Pages 31-38, February 2010

Traditional Statistical Methods for Evaluating Prediction Models Are Uninformative as to Clinical Value: Towards a Decision Analytic Framework

  • Andrew J. Vickers

      Affiliations

    • Corresponding Author InformationAddress correspondence to Andrew J. Vickers, PhD, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10065
  • ,
  • Angel M. Cronin

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Cancer prediction models are becoming ubiquitous, yet we generally have no idea whether they do more good than harm. This is because current statistical methods for evaluating prediction models are uninformative as to their clinical value. Prediction models are typically evaluated in terms of discrimination or calibration. However, it is generally unclear how high discrimination needs to be before it is considered “high enough”; similarly, there are no rational guidelines as to the degree of miscalibration that would discount clinical use of a model. Classification tables do present the results of models in more clinically relevant terms, but it is not always clear which of two models is preferable on the basis of a particular classification table, or even whether either model should be used at all. Recent years have seen the development of straightforward decision analytic techniques that evaluate prediction models in terms of their consequences. This depends on the simple approach of weighting true and false positives differently, to reflect that, for example, delaying the diagnosis of a cancer is more harmful than an unnecessary biopsy. Such decision analytic techniques hold the promise of determining whether clinical implementation of prediction models would do more good than harm.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by funds from David H. Koch provided through the Prostate Cancer Foundation, the Sidney Kimmel Center for Prostate and Urologic Cancers, and P50-CA92629 SPORE grant from the National Cancer Institute to Dr P.T. Scardino.

 The authors have no primary financial relationships with any companies directly interested in the subject matter of this manuscript.

PII: S0093-7754(09)00229-2

doi:10.1053/j.seminoncol.2009.12.004

Seminars in Oncology
Volume 37, Issue 1 , Pages 31-38, February 2010